- Trial Phase
- Approved (FDA approved June 11, 2025)
- Time to Market
- Already approved and commercializing (FDA approved June 2025). The sNDA decision for label expansion is expected by January 4, 2027.
- Why 6/10
- The next hard, dated catalyst is the sNDA PDUFA decision on January 4, 2027 (~4 months away). IBTROZI is Nuvation Bio's lead commercial asset and major value driver, but the primary approval binary has already passed, and the company also has safusidenib in Phase 3, so this is a label-expansion binary rather than a make-or-break event.
Watch for the sNDA PDUFA decision on January 4, 2027, which could expand the label and drive further commercial adoption. The ~80% implied upside to the mean analyst target and strong institutional ownership (FMR, BlackRock, Vanguard) support a bullish bias, but elevated short interest (~15.2% of outstanding) and insider selling via 10b5-1 plans warrant monitoring.
Price Chart
Executive Summary
Taletrectinib (brand name IBTROZI) is an FDA-approved ROS1 inhibitor for advanced ROS1-positive non-small cell lung cancer, developed and commercialized by Nuvation Bio (NYSE: NUVB). Approved June 11, 2025, it is already generating meaningful product revenue ($23.2M in Q2 2026) and is described as the most prescribed ROS1 TKI in new patient starts. The next hard catalyst is a January 4, 2027 PDUFA date for a supplemental NDA (sNDA) seeking to expand the label with updated efficacy data. Analyst consensus is Strong Buy with a mean price target of $13.10 (~80% upside from ~$6.93), though short interest is elevated at ~15.2% of outstanding shares.
How It Works
Taletrectinib is a targeted oral drug that blocks a protein called ROS1 found on some cancer cells. By inhibiting ROS1 (and also TRK), it stops signals that tell cancer cells to grow and divide, which can shrink tumors or slow their progression in patients with ROS1-positive non-small cell lung cancer.
Trial Status
Taletrectinib received FDA approval on June 11, 2025 for ROS1-positive NSCLC based on Phase 2 trial data. A supplemental NDA (sNDA) was accepted by the FDA in August 2026 with updated efficacy data in both TKI-naive and TKI-pretreated advanced ROS1+ NSCLC, with a target action date of January 4, 2027. The drug is already commercially launched and generating revenue.
The Two-Sided Case
Upcoming Catalysts
- January 4, 2027: PDUFA date for sNDA seeking label expansion with updated efficacy data in TKI-naive and TKI-pretreated advanced ROS1+ NSCLC
- Ongoing commercial adoption and quarterly revenue growth for IBTROZI
- Phase 3 SIGMA trial for safusidenib (IDH1-mutant glioma) — another pipeline asset
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Nuvation Bio Inc. 8-K NUVB ·Originating report